开云app官网登录入口网页版-官方正版

#阳性结果#

49篇内容 | 1621人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1642078, encodeId=7c2816420e81c, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？, objectType=article, longId=292989, objectId=e862292989a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e862292989a0, replyNumber=0, likeNumber=79, createdTime=2022-07-04, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e862292989a0, moduleTitle=普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e862292989a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642075, encodeId=34b116420e59f, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=撸猫有风险！抗体鸡尾酒REGN1908-1909治疗猫过敏性轻度哮喘，II期研究取得阳性结果, objectType=article, longId=207781, objectId=8ac120e78157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ac120e78157, replyNumber=0, likeNumber=68, createdTime=2021-05-11, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ac120e78157, moduleTitle=撸猫有风险！抗体鸡尾酒REGN1908-1909治疗猫过敏性轻度哮喘，II期研究取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8ac120e78157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642076, encodeId=557816420e62d, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果, objectType=article, longId=209280, objectId=187220928040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=187220928040, replyNumber=0, likeNumber=75, createdTime=2022-02-03, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=187220928040, moduleTitle=Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=187220928040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642077, encodeId=8b7a16420e72f, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力, objectType=article, longId=211778, objectId=aba2211e7815, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aba2211e7815, replyNumber=0, likeNumber=84, createdTime=2022-04-12, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aba2211e7815, moduleTitle=武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aba2211e7815)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642071, encodeId=d76516420e1bb, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果, objectType=article, longId=203133, objectId=529b20313392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=529b20313392, replyNumber=0, likeNumber=91, createdTime=2021-05-08, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=529b20313392, moduleTitle=XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=529b20313392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642070, encodeId=936c16420e00f, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, objectType=article, longId=202651, objectId=9ce020265159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ce020265159, replyNumber=0, likeNumber=80, createdTime=2021-02-07, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ce020265159, moduleTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9ce020265159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642074, encodeId=d23c16420e4c4, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果, objectType=article, longId=206667, objectId=b05220666ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b05220666ed0, replyNumber=0, likeNumber=65, createdTime=2021-12-10, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b05220666ed0, moduleTitle=武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b05220666ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642073, encodeId=f1bc16420e339, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Falkieri治疗双相抑郁症：II期临床取得了阳性结果, objectType=article, longId=205566, objectId=fd1d2055667a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd1d2055667a, replyNumber=0, likeNumber=61, createdTime=2021-08-17, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd1d2055667a, moduleTitle=Falkieri治疗双相抑郁症：II期临床取得了阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fd1d2055667a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642068, encodeId=323a164206815, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=NEJM：罗氟司特局部乳膏治疗慢性斑块状牛皮癣的2b期阳性结果, objectType=article, longId=197622, objectId=ae3b19e62262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae3b19e62262, replyNumber=0, likeNumber=80, createdTime=2020-10-19, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae3b19e62262, moduleTitle=NEJM：罗氟司特局部乳膏治疗慢性斑块状牛皮癣的2b期阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ae3b19e62262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642072, encodeId=679816420e235, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=ASH 2020：Momelotinib治疗血小板计数较低的中/高危骨髓纤维化患者，已取得阳性结果, objectType=article, longId=204323, objectId=f15a204323fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15a204323fa, replyNumber=0, likeNumber=80, createdTime=2021-02-25, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15a204323fa, moduleTitle=ASH 2020：Momelotinib治疗血小板计数较低的中/高危骨髓纤维化患者，已取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f15a204323fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642069, encodeId=e4d516420694d, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果, objectType=article, longId=202408, objectId=fdbb20240807, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdbb20240807, replyNumber=0, likeNumber=78, createdTime=2021-08-27, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdbb20240807, moduleTitle=呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fdbb20240807)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642064, encodeId=963b1642064cd, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果, objectType=article, longId=191477, objectId=26091914e7bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26091914e7bf, replyNumber=0, likeNumber=74, createdTime=2020-11-19, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26091914e7bf, moduleTitle=IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=26091914e7bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642060, encodeId=246c164206025, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果, objectType=article, longId=186746, objectId=f965186e4626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f965186e4626, replyNumber=0, likeNumber=75, createdTime=2020-12-12, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f965186e4626, moduleTitle=卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f965186e4626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642059, encodeId=cebb16420597a, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=传染性软疣的治疗：VP-102的III期CAMP试验取得阳性结果, objectType=article, longId=186578, objectId=36f11865e8b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36f11865e8b3, replyNumber=0, likeNumber=71, createdTime=2020-11-08, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36f11865e8b3, moduleTitle=传染性软疣的治疗：VP-102的III期CAMP试验取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=36f11865e8b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642056, encodeId=3d99164205604, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, objectType=article, longId=184397, objectId=4dad18439e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dad18439e2a, replyNumber=0, likeNumber=74, createdTime=2020-11-02, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dad18439e2a, moduleTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4dad18439e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642062, encodeId=86f0164206231, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, objectType=article, longId=188168, objectId=b557188168d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b557188168d1, replyNumber=0, likeNumber=72, createdTime=2020-08-18, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b557188168d1, moduleTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b557188168d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642067, encodeId=b9de164206eac, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=加环利定耳内局部制剂OTO-313治疗耳鸣，1/2期临床获得更佳阳性结果, objectType=article, longId=197189, objectId=a47719e1893d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a47719e1893d, replyNumber=0, likeNumber=102, createdTime=2020-10-03, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a47719e1893d, moduleTitle=加环利定耳内局部制剂OTO-313治疗耳鸣，1/2期临床获得更佳阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a47719e1893d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642061, encodeId=377a1642061c8, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, objectType=article, longId=187166, objectId=2f3218e16658, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f3218e16658, replyNumber=0, likeNumber=57, createdTime=2020-12-07, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f3218e16658, moduleTitle=礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2f3218e16658)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642052, encodeId=47dc1642052f6, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=鞘内注射AVXS-101治疗2型SMA患者的STRONG试验取得阳性结果, objectType=article, longId=180634, objectId=8340180634bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8340180634bd, replyNumber=0, likeNumber=60, createdTime=2020-04-16, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8340180634bd, moduleTitle=鞘内注射AVXS-101治疗2型SMA患者的STRONG试验取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8340180634bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642057, encodeId=15aa164205ed8, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, objectType=article, longId=184997, objectId=556218499e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556218499e7a, replyNumber=0, likeNumber=63, createdTime=2020-02-06, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556218499e7a, moduleTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=556218499e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

阳性结果

2020-05-29

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

普克鲁胺治疗轻中度新冠三期临床试验的期中分析未获阳性结果，给我们有哪些启示？

2022-07-04

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

撸猫有风险！抗体鸡尾酒REGN1908-1909治疗猫过敏性轻度哮喘，II期研究取得阳性结果

2021-05-11

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Medsenic宣布Arscimed®治疗慢性移植物抗宿主病(cGvHD)的II期临床研究取得阳性结果

2022-02-03

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力

2022-04-12

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果

2021-05-08

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果

2021-02-07

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果

2021-12-10

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Falkieri治疗双相抑郁症：II期临床取得了阳性结果

2021-08-17

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

NEJM：罗氟司特局部乳膏治疗慢性斑块状牛皮癣的2b期阳性结果

2020-10-19

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

ASH 2020：Momelotinib治疗血小板计数较低的中/高危骨髓纤维化患者，已取得阳性结果

2021-02-25

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

呼吸道合胞病毒（RSV）疫苗候选药物的I / II期试验：已取得阳性结果

2021-08-27

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果

2020-11-19

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果

2020-12-12

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

传染性软疣的治疗：VP-102的III期CAMP试验取得阳性结果

2020-11-08

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果

2020-11-02

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果

2020-08-18

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

加环利定耳内局部制剂OTO-313治疗耳鸣，1/2期临床获得更佳阳性结果

2020-10-03

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

礼来和Incyte宣布其口服JAK抑制剂Baricitinib在中度至重度特应性皮炎患者中进行的3期临床研究BREEZE-AD5的阳性结果

2020-12-07

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

鞘内注射AVXS-101治疗2型SMA患者的STRONG试验取得阳性结果

2020-04-16

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果

2020-02-06

科室
- - 订阅+
  - 更多科室
工具
服务